Bristol-Myers Squibb Rights
CELG.RT
28 hedge funds and large institutions have $234K invested in Bristol-Myers Squibb Rights in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Davenport & Co
Richmond,
Virginia
|
+$50K |
| 2 |
Selway Asset Management
|
+$11.3K |
| 3 |
Deltec Asset Management
New York
|
+$8.86K |
| 4 |
Private Wealth Partners
Mill Valley,
California
|
+$8.7K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$7.79K |
Top Sellers
CELG.RT Hedge Fund Activity: Q4 2019 in Review
28 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q4 2019, worth a combined $234K.
Buyers outnumbered sellers: 28 funds opened new CELG.RT positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Davenport & Co, opening a new position worth an estimated $50K.
- 28 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $234K of Bristol-Myers Squibb Rights stock for Q4 2019.
- 28 funds opened new Bristol-Myers Squibb Rights positions in Q4 2019 and 0 closed out, a net change of +28 holders.
- The largest Bristol-Myers Squibb Rights buyer in Q4 2019 was Davenport & Co, an estimated $50K added.
Based on aggregated 13F filings for Q4 2019.